絞り込み

16404

広告

神戸マラソンに約2万人 健脚競う (NHK)

阪神・淡路大震災で受けた支援への感謝と復興した町の様子を伝えようと始まった神戸マラソンが19日に行われ、およそ2万人が健脚を競いました。 神戸マラソンはことしで...

  1. 食物アレルギー 治療や検査で9人が重い症...
  2. 冬の登山に注意を 富士山登山道で呼びかけ...
  3. 歴史教科書、龍馬が消える? 高校の用語半...
  4. クルマ社会に革新をもたらす10の「注目ス...

ニュース一覧

Comparative study of effects of vonoprazan and esomeprazole on anti-platelet function of clopidogrel or prasugrel in relation to CYP2C19 genotype.

著者 Kagami T , Yamade M , Suzuki T , Uotani T , Hamaya Y , Iwaizumi M , Osawa S , Sugimoto K , Umemura K , Miyajima H , Furuta T
Clin Pharmacol Ther.2017 Sep 05 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (253view , 0users)

Full Text Sources

Drug-drug interaction between anti-acid and anti-platelet agents has not been fully elucidated. Vonoprazan, a new potassium competitive acid blocker, has been available in Japan. CYP2C19 and CYP3A4 are involved in the metabolism of clopidogrel, prasugrel, esomeprazole and vonoprazan. Using P2Y12 assay, we compared the effects of vonoprazan and esomeprazole on the anti-platelet functions of clopidogrel or prasugrel in 31 healthy Japanese volunteers [14 CYP2C19 homo-extensive (homo-EMs), 9 hetero-extensive (hetero-EMs), and 8 poor metabolizers (PMs)]. Vonoprazan decreased the median inhibition of platelet aggregation (IPA) values of clopidogrel and prasugrel more potently than esomeprazole (p < 0.001 for clopidogrel and p = 0.011 for prasugrel, respectively). Same tendencies were observed when stratified by CYP2C19 genotype groups (p = 0.004 in homo-EMs, 0.033 in hetero-EMs, and 0.043 in PMs). Vonoprazan attenuated the anti-platelet function of clopidogrel more potently than esomeprazole. Esomeprazole did not affect that of prasugrel irrespective of CYP2C19 genotype. (UMIN000019901) This article is protected by copyright. All rights reserved.
PMID: 28875498 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード